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Methods. The relationship between insertion/deletion (I/D)ACE genotype and ACE induced renoprotection in chronic
genotypes and proteinuria, rate of glomerular filtration rateproteinuric nephropathies.
decline (DGFR)—centrally evaluated by repeated measures ofBackground. Whether angiotensin-converting enzyme (ACE)
iohexol plasma clearance—and incidence of end-stage renalgene polymorphism affects disease progression and response
disease (ESRD) was prospectively evaluated in 212 patientsto ACE inhibitor therapy in nondiabetic proteinuric nephropa-
thies is not clearly established. with nondiabetic proteinuric chronic nephropathies enrolled
in the Ramipril Efficacy in Nephropathy (REIN) trial, where
patients were randomly assigned to ramipril or conventional
1 See Editorial by Hebert, p. 343. treatment.
Results. The DGFR 6 sem (20.38 6 0.09 vs. 20.50 6 0.082 Organization of the REIN Study: Principal investigators, G. Re-
muzzi, G. Tognoni; Study coordinator, P. Ruggenenti; Investigators vs. 20.36 6 0.06 mL/min/1.73 m2 per month) and incidence of
and Institutions (the number of patients available for genetic studies are ESRD (19 vs. 22 vs. 25%) in the three subgroups with the II,
in parentheses), R. Pisoni, L. Mosconi, T. Bertani (Div. di Nefrologia e ID, and DD genotypes, respectively, were comparable. Of note,
Dialisi, Ospedali Riuniti, Bergamo; N 5 108), A. Mazzi, G. Garini,
DGFR (20.28 6 0.07 vs. 20.43 6 0.09 mL/min/1.73 m2 perA. Borghetti (Istituto di Clinica Medica e Nefrologia, Parma; N 5 22),
month) and incidence of ESRD [14% vs. 36%, P 5 0.04, RRE. Oliva, C. Zoccali (Div. di Nefrologia Centro di Fisiologia Clinica
(95% CI), 2.62 (1.02 to 6.71)] were lower in ramipril than indel CNR, Reggio Calabria; N 5 18), R. Piperno, A. Rosati, M. Salvadori
conventionally treated patients in the DD genotype, but not(U. O. Nefrologia e Dialisi, Osp. Regionale 9Careggi-Monna Tessa’,
Firenze; N 5 17), G. Toti, S. Sisca, Q. Maggiore (Div. di Nefrologia in the II and ID genotype. Either at univariate (P 5 0.04)
e Dialisi, USL Zona 10H, Bagno a Ripoli; N 5 14), D. Dissegna, A. or at multivariate (P 5 0.01) analysis, ramipril significantly
Brendolan, G. La Greca (Div. di Nefrologia e Dialisi, Ospedale S. predicted a lower incidence of events in DD, but not in II and
Bortolo, Vicenza; N 5 11), F. Scanferla, G. Bazzato, S. Landini (Div. ID patients. At three months, ramipril decreased proteinuria
di Nefrologia e Dialisi Ospedale Provinciale Umberto I, Mestre; N 5 more effectively in DD (238.2%) than in the II (226.7%) or11), E. Pignone, R. Boero, G. Piccoli, F. Quarello (Div. di Nefrologia
ID (219.2%) genotype. In DD (but not in II or ID) ramipril-e Dialisi, Ospedale Zonale Giovanni Bosco, Torino; N 5 9), G. Gian-
treated patients, a short-term reduction in proteinuria corre-nico, O. Vitale, C. Manno, F.P. Schena (Div. di Nefrologia e Dialisi,
lated with DGFR over the entire follow-up period (P 5 0.02,Policlinico, Bari; N 5 7), F. Cofano, G. Fellin, G. D’Amico (Div. di
Nefrologia e Dialisi, Ospedale Provinciale S. Carlo Borromeo, Milano; r 5 20.41).
N 5 6), E. Gandini, I. D’Amato, A. Giangrande (U. O. Nefrologia e Conclusions. In nondiabetic proteinuric nephropathies, the
Dialisi, Ospedale Provinciale, Busto Arsizio; N 5 4), G. Garneri, F. ACE I/D polymorphism does not predict disease progression,
Giacchino (Div. di Nefrologia e Dialisi, Ospedale Provinciale, Ivrea; but is a strong predictor of ACE inhibition-associated renopro-N 5 2), A. Feriozzi, E. Ancarani (Div. di Nefrologia e Dialisi, Ospedale
tection in that proteinuria, DGFR, and progression to ESRDGrande di Viterbo, Viterbo; N 5 1), N. Bossini, B.F. Viola, F. Scolari,
are effectively reduced in patients with the DD, but not inR. Maiorca (Div. di Nefrologia e Dialisi, Spedali Civili, Brescia; N 5
those with the II or ID genotype.0). Statistical analyses, A. Perna, R. Benini, L. Tammuzzo (Istituto di
Ricerche Farmacologiche Mario Negri). Laboratory measurements, F.
Gaspari, F. Arnoldi, O Signorini, S. Ferrari, E. Guerini (Istituto di
Ricerche Farmacologiche Mario Negri). Independent adjudicating
panel, L. Migone (chairman), E. Marubini (statistician), A. Del Favero, In chronic proteinuric nephropathies, enhanced tubular
G. Ideo, E. Geraci, and U. Loi. reabsorption of proteins ultrafiltered in excess through
damaged glomeruli triggers a sequence of events thatKey words: proteinuria, angiotensin-converting enzyme, ramipril, ge-
notype, end-stage renal disease. contributes to progressive structural damage and renal
dysfunction [1]. It is specifically limited by drugs such asReceived for publication May 11, 1999
angiotensin-converting enzyme (ACE) inhibitors, whichand in revised form August 5, 1999
Accepted for publication August 23, 1999 ameliorate glomerular barrier size selectivity and reduce
glomerular protein ultrafiltration and proteinuria [1]. 2000 by the International Society of Nephrology
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Actually, at comparable levels of blood pressure control, morning before study drug administration) was reduced
to under 90 mm Hg. Other antihypertensive agents (butACE inhibitors limited proteinuria and progression to
end-stage renal disease (ESRD) in either diabetic [2] and not ACE inhibitors) were allowed to achieve and main-
tain the target blood pressure values. Each patient wasnondiabetic [3, 4] chronic nephropathies more effectively
than conventional antihypertensive drugs. examined by a physician at baseline, every month during
the first three months after randomization, and everyAt comparable levels of urinary proteins and blood
pressure control, however, chronic nephropathies may three months thereafter. At baseline, at one, three, and
six months after randomization, and at every six monthsdiffer in their outcome and response to equivalent doses
of ACE inhibitors [5, 6]. This does not necessarily relate thereafter, patients had their glomerular filtration rate
(GFR) centrally evaluated at the Mario Negri Instituteto differences in clinical characteristics of patients en-
rolled in controlled trials because the rate of disease pro- for Pharmacological Research (Bergamo, Italy) by the
plasma clearance of nonradioactive iohexol [21]. Urinarygression and the response to ACE inhibition were some-
how independent of the underlying renal pathology [3–8] protein excretion was measured by the biuret precipita-
tion method [22] in all participating centers in orderand, in some studies, even of the degree of renal impair-
ment [9]. A diverse genetic background might rather be to minimize variation in protein measurement. Blood
samples were collected and stored at the laboratories ofimplicated [10]. Candidate genes that predispose to renal
disease progression chiefly include the gene-encoding the “Consiglio Nazionale delle Ricerche,” University of
Calabria for centralized evaluation of ACE polymor-renin-angiotensin system (RAS) proteins, and special
emphasis has been devoted to ACE [10–12]. Plasma levels phism. The main objective of the study was to compare
the effect of the two study treatments (ramipril vs. con-of ACE are indeed under genetic control being strongly
dependent on an insertion/deletion (I/D) polymorphism ventional) on DGFR and progression to ESRD in pa-
tients with comparable levels of blood pressure controlof the corresponding gene, defined by the presence or
absence of a 278 bp Alu-repetitive sequence in the intron and different ACE genotypes.
According to the Declaration of Helsinki, all patients16 of the 17 chromosome [13, 14]. The D allele is a recog-
nized marker of atherosclerotic complications, but it is provided signed written informed consent before study
entry.still uncertain whether this allele is related to renal dis-
ease progression or whether it may predict the response
Determination of angiotensin-convertingto ACE inhibition [15–19].
enzyme genotypesTo address this issue, we tested the hypothesis that
different ACE genotypes predicted different outcomes Nuclear DNA was extracted from peripheral leuko-
cytes in whole blood samples by salting out. A 25 ngin a large cohort of patients with nondiabetic, proteinuric
nephropathies enrolled in the Ramipril Efficacy in Ne- genomic DNA was amplified by polymerase chain reac-
tion (PCR; Perkin-Elmer 9600, Norwalk, CT, USA) inphropathy (REIN) study, who were randomly assigned
to ACE inhibitor or conventional antihypertensive treat- a 25 mL mixture of 1.5 mmol/L MgCl2, 50 mmol/L KCl
(pH 8.3), 0.001% gelatin, 200 mmol/L deoxynucleotidement [3, 4, 20].
triphosphates, 0.48 mmol/L primers, and 1 U Taq polymer-
ase (Ampli-Taq; Perkin-Elmer). The forward and re-
METHODS
verse primers were, respectively, 59-CTGGAGACCAC
Study design TCCCATCCTTTCT-39 and 59-GATGTGGCCATCAC
ATTCGTCAGAT-39. Thirty cycles of thermocyclingA detailed description of the REIN study design and
results has been published elsewhere [3, 4, 20]. The active with one minute of denaturation at 948C, one minute of
annealing at 638C, and two minutes of extension at 728C,treatment and placebo were supplied by Hoechst AG
(Frankfurt am Main, Germany). Study participants were followed by five minutes of final extension at 728C were
performed. The final products, two fragments, one ofpatients of either sex and were between 18 and 70 years
old, with urinary protein excretion $1 g/24 hours over 490 bp with insertion (I allele) and one of 190 bp without
(D allele), were detected on 1.5% agarose gel.at least three months and a creatinine clearance in the
range of 20 to 70 mL/min/1.73 m2. The D allele was preferentially amplified. To avoid
the possibility of mistyping the ID eterozygotes as DDAccording to the baseline urinary protein excretion
rate, before randomization, patients were separated into homozygotes, all DD samples were reamplified by a sec-
ond primer pair specific for the inserted I sequence. PCRtwo strata (stratum 1, 1.0 to 2.9 g/24 hours; stratum 2,
$3 g/24 hours) and were then randomly assigned 1.25 was performed in a 25 mL mixture of 1.5 mmol/L MgCl2,
50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 8.8), 0.1%mg capsules of ramipril or of placebo on a 1:1 basis
within each stratum. The study-drug dose was increased Triton X-100, 200 mmol/L deoxynucleotide triphosphates,
0.4 mmol/L primers, 3 U Taq polymerase, and 100 ngevery two weeks up to 2.5 mg/day or 5 mg/day until
“trough” diastolic blood pressure (measured in the genomic DNA. The primers for the inserted sequence
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were 59-TGGGACCACAGCGCCCGCCACTAC-39 and (Fig. 1). In the three genotypes, the overall (that is,
regardless of treatment group) blood pressure control59-TCGCCAGCCCTCCCATGCCCATAA-39.
Forty cycles of thermocycling with one minute of dena- and 24-hour urinary protein excretion rate during the
whole follow-up period were comparable as well (Tableturation at 948C, followed by one minute of annealing-
extension at 788C, and a 10-minute final extension at 2). Of note, both at univariate and multivariate analyses,
including also blood pressure, proteinuria and all rele-728C were performed. Only the I allele produced a 300
bp fragment, whereas no products were detected with the vant baseline covariates, the I/D genotype was not sig-
nificantly associated with DGFR or ESRD.DD genotype, which assured the absence of mistyping.
As expected, in the whole cohort DGFR (6sem) and
Statistical analysis incidence of ESRD were lower in patients on ramipril
(20.39 6 0.06 mL/min/1.73 m2/month and 18.1%, respec-Baseline and time-dependent covariates were evalu-
ated in all the 212 patients with available information tively) as compared with patients on conventional treat-
ment (20.47 6 0.06 mL/min/1.73 m2/month and 28%,on ACE polymorphism randomized in the REIN study.
Individual GFR declines were estimated by linear regres- respectively). Data in the II, ID, and DD genotypes are
given in Figures 2 and 3. Of note, DGFR and incidencesion model (least-squares method). Only patients with
at least three GFR evaluations (including baseline) were of events (Figs. 2 and 3) were lower in ramipril as com-
pared with conventionally treated patients only in theconsidered to derive GFR slopes.
A correlation analysis between ACE genotype, treat- DD subgroup, even if the difference in DGFR failed to
achieve statistical significance. Thus, in this subgroup,ment and other baseline and follow-up covariates, and
GFR slopes was univariately carried out using Pearson’s kidney survival was significantly higher on ramipril than
on conventional treatment (Fig. 4). In contrast, bothr correlation coefficient for continuous variables and us-
ing point-biserial correlation coefficient for dicothomous DGFR and events were comparable between ramipril
and conventionally treated patients in either the II or invariables [23]. Multivariate analysis was performed using
the ID subgroup (Figs. 2 and 3). Of note, even aftermultiple linear regression [24]. Renal end points, dialysis,
adjustments for different treatment effect in the differentor transplantation were univariately and multivariately
subgroups, multivariate analysis found no significant as-analyzed by Cox’s proportional hazards model [25]. The
sociation between ACE genotype and incidence ofrole of treatment (ramipril or placebo) as time-depen-
events. When, to definitely rule out any potentially dis-dent covariate was evaluated in the overall study popula-
turbing effect of different responses to ramipril, analysestion and separately in the three subgroups of patients
were restricted to patients on conventional treatment, awith the II, ID, and DD genotypes. Comparisons be-
trend to a higher incidence of events in the DD than intween genotypes were done using Wilcoxon rank-sum
the II or ID genotype was observed. Again, however,test, Fisher’s exact test, or log-rank test as appropriate.
the association between genotype and events failed toFollow-up values were compared by analysis of covari-
achieve the statistical significance.ance adjusting for baseline measurements. Data analyses
Within the ID and the DD subgroups, ramipril andwere performed using the SAS System (release 6.12).
conventionally treated patients had virtually identicalData were expressed as mean 6 sem or as a percentage,
systolic and diastolic blood pressure control throughoutunless otherwise stated. Statistical significance was set
the entire study period (Table 2). In contrast, within theat 0.05 level (two-tailed).
II subgroup, systolic and diastolic blood pressures were
lower among ramipril than among conventionally treated
RESULTS patients, with differences being statistically significant
Main clinical and laboratory parameters in the overall for the diastolic values (Table 2). On the other hand,
study population and in the three subgroups of patients within the ID and the DD subgroups, those treated with
with the II, ID, or DD genotype are listed in Table 1. ramipril, as compared with conventionally treated pa-
A comparable proportion of patients in the whole study tients, had a significantly lower 24-hour urinary protein
group and within each subgroup was on ramipril or con- excretion rate throughout the whole study period. In
ventional treatment (Table 1). Baseline characteristics contrast, among the II genotype patients, the 24-hour
of ramipril and conventionally treated patients were urinary protein excretion rate was comparable between
comparable in the whole study group and within each the two treatment groups. Thus, among ID and DD
I/D subgroup (data not shown). In the whole cohort, patients, ramipril decreased proteinuria more effectively
over a median (range) follow-up of 30.3 (1.0 to 76.1 than conventional treatment, even at comparable levels
months), DGFR (6 sem) was 20.45 6 0.05 mL/min/ of blood pressure control. In contrast, in the II genotype
1.73 m2/month, and the incidence of ESRD was 23.1%. group, ramipril, as compared with conventionally treated
DGFR and incidence of ESRD in the three subgroups patients, had no additional effect on proteinuria, despite
a greater blood pressure reduction.with the II, ID, and DD genotypes were comparable
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Table 1. Overall and per insertion/deletion (I/D) genotype baseline characteristics of 212 patients with chronic renal insufficiency and
urinary protein excretion rate .1 g/24 hours
Genotype
II ID DD Overall
Patients (N) 26 99 87 212
On ramipril treatment % 61.5 47.5 48.2 49.5
Demographics
Age years 47.8615.5 47.5614.3 52.1613.3 49.4614.1
Male sex % 88.5 73.7 71.3 74.5
Renal disease
Glomerular disease % 50 49.5 51.7 50.5
APKD or interstitial nephritis % 0 4.0 5.8 4.2
Other or unknown % 50 46.5 42.5 45.3
Renal function indicators
GFR ml/min/1.73 m2 47.5621.9 43.0618.9 42.2618.1 43.2618.9
CCr ml/min/1.73 m2 56.3620.6 47.5617.2 47.1620.3 48.4619.1
Serum creatinine mg/dl 2.0460.80 2.1660.87 2.1960.96 2.1660.90
Urinary protein excretion g/24 h 3.4562.37 3.5562.33 2.8561.69 3.2562.11
Urinary urea excretion g/24 h 22.069.0 19.868.9 18.668.8 19.668.9
Urinary sodium excretion mEq/24 h 174.6663.7 189.2699.6 165.3675.7 177.7687.0
Arterial blood pressure
Systolic mmHg 149.5617.4 145.8617.2 146.8618.3 146.7617.6
Diastolic mmHg 93.4610.2 89.8613.2 89.3610.6 90.0611.9
Mean mmHg 112.1611.3 108.5613.2 108.5611.9 108.9612.5
Hypertensive patients
Overall % 84.6 78.8 85.1 82.1
On antihypertensive therapy % 61.5 66.7 66.7 66.0
Serum biochemistry
Total cholesterol mg/dL 226.3652.1 250.8657.0 241.0673.6 243.7664.2
Triglycerides mg/dL 123.3655.8 195.26135.6a 189.56148.7 184.06135.9
Potassium mEq/L 4.4160.69 4.3960.58 4.660.52 4.4660.58
Data are mean 6 sd or percent values.
a P , 0.01 vs. II genotype (after Bonferroni adjustment)
Of note, throughout the entire study period, ramipril-
treated patients had virtually identical blood pressure
control in the three genotypes. However, to achieve such
comparable level of blood pressure control, higher doses
of ramipril were required in II than in ID or DD patients.
Actually, II patients received (mean 6 sd) 0.053 6 0.021
mg of ramipril per kg body weight as compared with
0.038 6 0.020 mg/kg (P 5 0.014) and 0.040 6 0.021
mg/kg (P 5 0.05) in ID and DD patients, respectively.
In contrast, the ramipril dose was comparable in ID and
DD patients (P 5 0.52).
Thus, the II genotype patients had no reduction in
proteinuria, DGFR, and events, despite the fact that they
were exposed to higher doses of ramipril as compared
with ID and DD patients. In contrast, regardless of the
ramipril dose and of blood pressure control, DD patients
showed a remarkably better response to ramipril than
II and ID patients.
Actually, either at univariate or multivariate analysis,
ramipril treatment significantly predicted a lower inci-
dence of events in DD (Table 3), but not in II and ID
patients. At three months, ramipril decreased urinary
proteins more effectively in the DD and in the II thanFig. 1. Rate of glomerular filtration rate (DGFR; A) and incidence of
events (B) according to different insertion/deletion (I/D) genotypes. in the ID subgroup (Fig. 5). Of note, in DD ramipril-
treated patients, the short-term percentage reduction in
urinary proteins significantly correlated with the DGFR
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Table 2. Systolic and diastolic blood pressure and 24-hour urinary protein excretion rate in patients with the II, ID, and DD genotype as
a whole (overall) and according to conventional or ramipril treatment
II ID DD
Systolic blood pressure mmHg
Conventional 144.064.7 143.2 61.8 142.8 62.1
Ramipril 139.764.6 139.0 62.6 139.8 62.3
Overall 141.463.3 141.3 61.5 141.3 61.6
Diastolic blood pressure mmHg
Conventional 92.162.0 88.6 61.4 87.4 61.1
Ramipril 85.361.5a 86.161.5 86.2 61.1
Overall 88.061.4 87.4 61.0 86.8 60.8
Urinary protein excretion rate g/24 hours
Conventional 3.0860.53 3.65 60.27 2.73 60.21
Ramipril 3.4160.87 2.79 60.29a 2.2860.23a
Overall 3.2760.56 3.24 60.20 2.52 60.16
a P # 0.01 vs. conventional
Fig. 3. Incidence of events according to ramipril ( ) or conventional
( ) treatment and different I/D genotypes.
Fig. 2. DGFR according to ramipril ( ) or conventional ( ) treatment
and different I/D genotypes.
size, the short duration of follow-up, and the rather im-
precise evaluation of renal function.
over the whole follow-up period (Fig. 6). No correlation Here, in a large enough cohort of patients with nondia-
between the two parameters was found in II and ID betic chronic nephropathies studied by repeated mea-
patients or in conventionally treated patients. surements of true GFR, we consistently failed to docu-
ment any association between ACE I/D polymorphism
and disease progression. Patients showed the sameDISCUSSION
course of GFR and the same incidence of events over
Thus far, the role of I/D polymorphism in the risk of time, irrespective of I/D genotype. Of note, failure to
progression of nondiabetic renal diseases has not been document at multivariate analysis any significant associa-
well defined. Some studies simply based on serum creati- tion between ACE genotype and renal outcome—even
nine or creatinine clearance measurements found that after adjustments for treatment effects or exclusion of
progression was faster in DD genotypes, whereas others ramipril treatment patients—argued against any rele-
have been unable to confirm this finding [15–17, 19]. Of vant, independent predictive value of the ACE genotype.
particular interest is a study in IgA nephropathy that This is in contrast with a previous study showing faster
found a tendency toward an increased frequency of the progression of chronic renal disease in patients with the
DD genotype in those patients who progressed to ESRD DD genotype [18]. This study, however, included only
compared with those who instead had evidence of stable 17 DD patients, and its results might have been influ-
renal function [15]. When interpreting the results of stud- enced by random fluctuations of data. Moreover, more
ies so far available on this subject, one should consider patients with adult polycystic kidney disease (APKD)
were represented in the DD than in the II or ID subgroupthat all were considerably limited by the small sample
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Fig. 4. Kidney survival according to ramipril
or conventional treatment in patients with DD
genotype. Ramipril, d (6 events); conven-
tional treatment, s (16 events).
Table 3. Univariate and multivariate analysis of the correlation(24 vs. 11%). Thus, the higher prevalence of APKD,
between baseline parameters and progression to end-stage renal
which is a recognized cause of fast disease progression disease (ESRD) in the subgroup of patients with the DD genotype
regardless of concomitant treatments, rather than the
Baseline parameters Univariate Multivariategenotype per se, might have accounted for the poorest
Clinical parametersrenal outcome observed in the DD subgroup.
Age 0.80 0.99
This study is also the first one that prospectively ad- Sex 0.84 0.34
Mean blood pressure 0.43 0.26dressed the renoprotective effect of ACE inhibitor ther-
Diagnosis 0.80 0.54apy in the context of different ACE genotypes under
Ramipril treatment 0.045 0.01
careful monitoring of blood pressure and standardized Laboratory parameters
Urinary protein excretion 0.0092 0.0035conditions of sodium and protein intake. Even more
GFR 0.0001 0.0001important, this study, but none of the previous ones, had
Total cholesterol 0.93 0.96
enough power to detect an effect of the treatment on Triglycerides 0.37 0.38
hard end points such as risk of ESRD or need for dialysis.
Here we found that independent of the nature of the
underlying disease, the I/D polymorphism of the ACE
gene is the strongest predictor of response to ACE inhib- mal among patients who completely miss the D allele.
itor therapy. Thus, among patients with the DD geno- Of note, these different trends were not accounted for
type, those on ramipril had a consistent reduction in by different characteristics at baseline (particularly in
urinary proteins, DGFR, and risk of ESRD as compared prevalence of underlying diseases and extent of protein-
with those on conventional treatment. A similar trend uria) or by different blood pressure control. Actually, in
in proteinuria and, even if less consistent and never statis- DD (and to a less extent in ID) patients, ramipril de-
tically significant, in DGFR and events was observed creased proteinuria, DGFR, and events more effectively
among patients with the ID genotype. In contrast, uri- than conventional treatment at a comparable level of
nary proteins, DGFR, and incidence of events were virtu- blood pressure control. In contrast, in II patients, rami-
ally identical on ramipril or conventional treatment pril had no specific effect on proteinuria despite better
among patients with the II genotype. These data would blood pressure control.
imply that the extent of the response to ramipril reflects Of note, among ramipril-treated patients, blood pres-
the distribution of the D allele, being maximal in DD sure control was almost identical within each ACE geno-
type. To achieve the same blood pressure control, how-homozygotes, intermediate in ID eterozygotes, and mini-
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Fig. 5. Median percentage reduction in urinary protein excretion rate
at three months versus baseline values according to ramipril ( ) or
conventional ( ) treatment and different I/D genotypes.
Fig. 6. Correlation between median three-month percentage changes
in urinary protein excretion rate and DGFR during the whole follow-
up period in patients with DD genotype. N 5 33; r 5 20.41; P 5 0.02.
ever, higher doses of ramipril were needed in the II
subgroup. Finding that, despite using higher doses, rami-
pril was virtually devoided of any effect on proteinuria,
DGFR and events in II patients, further corroborated genotype groups in nondiabetic patients with various
the hypothesis that the ACE allele I confers a specific renal diseases (abstract; van der Kleij et al, J Am Soc
refractoriness to ACE inhibition. In contrast, the D allele Nephrol 7:1326, 1996). Conflicting with these results were
would have the opposite effect and would confer to DD data from an Austrian study showing that over six weeks
patients the highest sensitivity to ACE inhibition. These of treatment, patients with nephrotic renal disease of
findings are at variance with preliminary data, suggesting variable etiology bearing with ID or II genotype exhib-
that DD patients were poor responders to ACE inhibi- ited a significantly more marked antiproteinuric response
tors [18]. In this study, however, APKD and interstitial
to ACE inhibitor treatment that did patients with DD
disease were more frequent in the DD than in the II or
genotype (abstract; Schmidt et al, J Am Soc NephrolID subgroups and accounted for almost 60% of the DD
7:1398, 1996). This study, however, provided no data onpatients (vs. only 33% of II or ID patients). Thus, the
disease progression in the long term.higher prevalence of patients with a form of chronic
In conclusion, this study demonstrated that in nondia-renal disease that—being associated with only mild or no
betic proteinuric nephropathies, ACE I/D polymorphismproteinuria—usually does not specifically benefit from
(a) does not predict disease progression and (b) is aACE inhibition therapy [1, 7], rather than the genotype
strong predictor of ACE inhibition-associated renopro-per se, might have accounted for the poor response to
tection in that DGFR and incidence of ESRF were maxi-ACE inhibition previously observed in association with
mally prevented in patients with the DD genotype and,the DD genotype.
to a less extent, in those with the ID genotype. PatientsFinding that, among patients with the DD genotype,
with the II genotype instead had no specific advantagesslower DGFR in the long term tended to correlate with
a short-term reduction in urinary proteins suggests that from ACE inhibition as compared with conventional
these patients had a superior benefit from ACE inhibi- antihypertensives.
tion having a higher susceptibility to the antiproteinuric Whether the II genotype reflects a condition of abso-
effect of the drug. However, the possibility that the im- lute refractoriness to the renoprotective effect of ACE
proved outcome of DD patients depended even on other inhibitors or whether higher doses of these agents were
mechanisms directly influenced by ACE inhibition can- possibly needed to achieve a consistent response needs
not be ruled out by these data. further study.
In harmony with these findings, two previous series
of Japanese patients with IgA nephropathy found more
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